These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 23647169)

  • 1. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.
    Stone TW; Darlington LG
    Br J Pharmacol; 2013 Jul; 169(6):1211-27. PubMed ID: 23647169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Developments in the Design of Inhibitors along the Kynurenine Pathway.
    Jacobs KR; Castellano-Gonzalez G; Guillemin GJ; Lovejoy DB
    Curr Med Chem; 2017; 24(23):2471-2495. PubMed ID: 28464785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
    Dounay AB; Tuttle JB; Verhoest PR
    J Med Chem; 2015 Nov; 58(22):8762-82. PubMed ID: 26207924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.
    Valor LM; Viosca J; Lopez-Atalaya JP; Barco A
    Curr Pharm Des; 2013; 19(28):5051-64. PubMed ID: 23448461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
    Boros FA; Bohár Z; Vécsei L
    Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.
    Zhang S; Collier MEW; Heyes DJ; Giorgini F; Scrutton NS
    Arch Biochem Biophys; 2021 Jan; 697():108702. PubMed ID: 33275878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
    Phillips RS; Anderson AD; Gentry HG; Güner OF; Bowen JP
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1705-1708. PubMed ID: 28302400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
    Zarzecki MS; Cattelan Souza L; Giacomeli R; Silva MRP; Prigol M; Boeira SP; Jesse CR
    Neurochem Res; 2020 Dec; 45(12):2959-2977. PubMed ID: 33040279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.
    Réus GZ; Becker IRT; Scaini G; Petronilho F; Oses JP; Kaddurah-Daouk R; Ceretta LB; Zugno AI; Dal-Pizzol F; Quevedo J; Barichello T
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():55-63. PubMed ID: 29030243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).
    Zádori D; Veres G; Szalárdy L; Klivényi P; Fülöp F; Toldi J; Vécsei L
    Expert Opin Ther Pat; 2016 Jul; 26(7):815-32. PubMed ID: 27172114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.
    Amaral M; Outeiro TF; Scrutton NS; Giorgini F
    J Mol Med (Berl); 2013 Jun; 91(6):705-13. PubMed ID: 23636512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone post-translational modifications to target memory-related diseases.
    Monti B
    Curr Pharm Des; 2013; 19(28):5065-75. PubMed ID: 23448462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases.
    Bose S; Cho J
    Arch Pharm Res; 2013 Sep; 36(9):1039-50. PubMed ID: 23771498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease.
    Jones SP; Franco NF; Varney B; Sundaram G; Brown DA; de Bie J; Lim CK; Guillemin GJ; Brew BJ
    PLoS One; 2015; 10(6):e0131389. PubMed ID: 26114426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity.
    Liu JJ; Raynal S; Bailbé D; Gausseres B; Carbonne C; Autier V; Movassat J; Kergoat M; Portha B
    Biochim Biophys Acta; 2015 May; 1852(5):980-91. PubMed ID: 25675848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of kynurenine 3-monooxygenase inhibition.
    Amaral M; Levy C; Heyes DJ; Lafite P; Outeiro TF; Giorgini F; Leys D; Scrutton NS
    Nature; 2013 Apr; 496(7445):382-5. PubMed ID: 23575632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tryptophan metabolism along the kynurenine pathway in diet-induced and genetic hypercholesterolemic rabbits.
    Allegri G; Ragazzi E; Costa CV; Caparrotta L; Biasiolo M; Comai S; Bertazzo A
    Clin Chim Acta; 2004 Dec; 350(1-2):41-9. PubMed ID: 15530458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Precision Small-Molecule Proneurotrophic Therapies for Neurodegenerative Diseases.
    Janssens J; Lu D; Ni B; Chadwick W; Siddiqui S; Azmi A; Etienne H; Jushaj A; van Gastel J; Martin B; Maudsley S
    Vitam Horm; 2017; 104():263-311. PubMed ID: 28215298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.
    Sathyasaikumar KV; Breda C; Schwarcz R; Giorgini F
    Methods Mol Biol; 2018; 1780():397-413. PubMed ID: 29856028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.